Proliferation is the main epidermal target in the treatment of psoriatic plaques with once daily application of tacalcitol ointment

Acta Dermato-Venereologica

Volumn 79, Issue 2, 1999, Pages 111-114

  Castelijns, Fransje A C M ^a   Gerritsen, Marie Jeanne P ^a   Van Vlijmen Willems, Ivonne M J J ^a   Van Erp, Piet J ^a   Van De Kerkhof, Peter C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidermis; Immunohistochemistry; Psoriasis; Vitamin D3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KERATIN; KI 67 ANTIGEN; TACALCITOL;

ADULT; ARTICLE; CASE REPORT; DRUG EFFECT; DRUG EFFICACY; EPIDERMIS; FEMALE; GROWTH REGULATION; HUMAN; KERATINIZATION; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PSORIASIS; TISSUE DISTRIBUTION;

EID: 0033010519     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155599750011309     Document Type: Article

References (28)

1. van de Kerkhof PCM, Werfel T, Haustein UF, Luger T, Czarnetzki BM, Niemann R, et al. Tacalcitol ointment in the treatment of psoriasis vulgaris a multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 1996; 135: 758-765.
2. Veien NK, Bjerke JR, Rossmann Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 1997; 137: 581-586.
3. Gerritsen MJP, Boezeman JBM, van Vlijmen-Willems IMJJ, van de Kerkhof PCM. The effect of tacalcitol (1, 24 (OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double-blind study. Br J Dermatol 1994; 131: 57-63.
4. Glade CP, van Erp PEJ, van Hooijdonk CAEM, Elbers ME, van de Kerkhof PCM. Topical treatment of psoriatic plaques with 1 alpha.24 dihydroxyvitamin D3: a multiparameter flow cytometrical analysis of epidermal growth, differentiation and inflammation. Acta Derm Venereol (Stockh) 1995; 75: 381-385.
5. Mommers JM, Castelijns FACM, Seegers BAMPA, van Rossum MM, van Hooijdonk CAEM, van Erp PEJ, et al. The effect of long-term treatment with tacalcitol on the psoriatic epidermis. A flow cytometric analysis. Br J Dermatol 1998; 139: 468-471.
6. Gerritsen MJP, van Erp PEJ, van de Kerkhof PCM. Transglutaminase-positive cells in psoriatic epidermis during treatment with calcitriol (1alpha,25 dihydroxy vitamin D3) and tacalcitol (1alpha,24 dihydroxy vitamin D3). Br J Dermatol 1995; 133: 656-659.
7. Baudet C, Chevalier G, Naveilhan P, Binderup L, Brachet P, Wion D. Cytotoxic effects of 1alpha,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line. Cancer Letters 1996; 100: 3-10.
8. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
9. Purkis PE, Steel JB, Mackenzie IC, Nathrath WB, Leigh IM, Lane EB. Antibody markers of basal cells in complex epithelia. J Cell Sci 1990; 97: 39-50.
10. Perkins W, Campbell I, Leigh IM, MacKie RM. Keratin expression in normal skin and epidermal neoplasms demonstrated by a panel of monoclonal antibodies. J Cutan Pathol 1992; 19: 476-482.
11. Markey AC, Lane EB, MacDonald DM, Leigh IM. Keratin expression in basal cell carcinomas. Br J Dermatol 1992; 126: 154-160.
12. Stoler A, Kopan R, Duvic M, Fuchs E. Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. J Cell Biol 1988; 107: 427-446.
13. Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, Riddle PN. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol 1995; 133: 501-511.
14. King LE Jr, Gates RE, Stoscheck CM, Nanney LB. Epidermal growth factor/transforming growth factor alpha receptors and psoriasis. J Invest Dermatol 1990; 95: 10S-12S.
15. King LE Jr, Gates RE, Stoscheck CM, Nanney LB. The EGF/TGF alpha receptor in skin. J Invest Dermatol 1990; 94: 164S-170S.
16. Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-363.
17. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
18. de Mare S, de Jong EMG, van Erp PEJ, van de Kerkhof PCM. Markers for proliferation and keratinization in the margin of the active psoriatic lesion. Br J Dermatol 1990; 122: 469-475.
19. de Jong EMG, Schalkwijk J, van de Kerkhof PCM. Epidermal proliferation and differentiation, composition of the inflammatory infiltrate and the extracellular matrix in the margin of the spreading psoriatic lesion. Eur J Dermatol 1991; 1: 221-227.
20. Braun Falco O, Christophers E. Structural aspects of initial psoriatic lesions. Arch Dermatol Forsch 1974; 251: 95-110.
21. Soltani K, Van Scott EJ. Patterns and sequence of tissue changes in incipient and evolving lesions of psoriasis. Arch Dermatol 1972; 106: 484-490.
22. de Jong EMG, van de Kerkhof PCM. Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: modulations and interrelations. Br J Dermatol 1991; 124: 221-229.
23. de Jong EMG, Ferrier CM, de Zwart A, Wauben Penris PJ, Korstanje C, van de Kerkhof PCM. Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci 1995; 9: 185-194.
24. Vallat VP, Gilleaudeau P, Battat L, Wolfe J, Nabeya R, Heftler N, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994; 180: 283-296.
25. Hashimoto K, Matsumoto K, Higashiyama M, Iwasa M, Hashiro M, Ueda K, et al. 1alpha,25-dihydroxyvitamin D3 inhibits cell growth and decreases high-affinity receptors for EGF in human keratinocytes derived from psoriatic lesions. J Invest Dermatol 1989; 92: 440.
26. Kerneny L, Michel G, Arenberger P, Ruzicka T. Down-regulation of epidermal growth factor receptors by dithranol. Acta Derm Venereol (Stockh) 1993; 73: 37-40.
27. Esgleyes Ribot T, Chandraratna RA, Lew Kaya DA, Sefton J, Duvic M. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1994; 30: 581-590.
28. Wrone Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickoloff BJ. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997; 151: 1321-1329.